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We previously reported a 48-year-old white man with CML who developed alopecia areata 15 months after receiving a allo-SCT from his HLA-identical brother with alopecia areata. 2 We now report a second patient, a 55-year-old white female with AML, who developed alopecia areata 16 months after receiving an allo-SCT, from her brother with AU.
The patient was treated with idarubicin and cytarabine, followed by a high-dose cytarabine resulting in CR. She relapsed 3 years later and was re-induced into a second CR with salvage therapy with clofarabine, idarubicin and cytarabine, followed by a T-cell replete allo-SCT from her HLA-matched 40-year-old brother. At the time of transplant, her brother had longstanding, clinically active AU, the most severe phenotype of alopecia areata with total body hair loss. The patient's brother was first diagnosed with AU by his dermatologist in 1983 and never experienced hair regrowth.
The patient's transplant preparative regimen consisted of BU and fludarabine, and her graft versus host disease (GVHD) prophylaxis consisted of tacrolimus (7 mg daily, later reduced) and mini-dose MTX. She achieved full donor chimerism 12 months post transplant, and she remains in remission as of her last restaging assessment 3 years post transplant. She did not develop any acute GVHD peri-transplant, and her tacrolimus was discontinued 10 months post transplant. She developed limited chronic GVHD in the form of dyspareunia and vaginal dryness at 10 months following allo-SCT.
The patient experienced initial diffuse hair loss on her scalp due to chemotherapy with subsequent thin, sparse hair regrowth on all areas. Sixteen months post allo-SCT, she developed patchy areas of hair loss on the top of her scalp consistent with alopecia areata. The patient was not diagnosed with alopecia areata previously because it was initially believed that chemotherapy was the cause of sparse hair regrowth, and then the patient was later suspected to be experiencing GVHD by her leukemia physician. The alopecia patches progressed to complete baldness at the top of the scalp (Figure 1a) . The patient also presented with patches of hair loss in the lateral, parietal and frontal regions of the scalp. On examination, she also had hair loss in her eyebrows and some of her eyelashes were missing. She was treated with fluocinonide 0.05% solution and topical minoxidil 5% solution, both medications which are effective in treating alopecia areata in nontransplant patients.
3,4 Four months later, there was good partial regrowth of her hair on the top of the scalp but areas of complete loss remained on the lateral parietal scalp (Figure 1b) . A punch biopsy specimen taken from the right side of the scalp showed lymphocytic infiltrate around the lower portion of the hair follicle ( Figure 2a ) and a peribulbar lymphocytic infiltrate (Figure 2b ) characteristic of alopecia areata, as opposed to the lichenoid pattern commonly seen in GVHD. FISH performed on the scalp biopsy showed that the peribulbar lymphocytes were a mixture of both host (XX) and donor (XY) lymphocytes (Figure 2c) , supporting a diagnosis of donor-induced alopecia areata rather than other causes of hair loss. This is only the second reported case of alopecia areata post-HLA-matched allo-SCT from a sibling. Alopecia areata is an organ restricted, autoimmune disorder in which T lymphocytes attack hair follicles, disrupting the normal hair growth cycle, and causing hair breakage and baldness in patches. The onset of alopecia areata post allo-SCT lends support to a T-cell-mediated pathogenesis, suggesting that it may be immunologically mediated by the means of transmission from stem cell donor to recipient. 2, 5, 6 Other causes of alopecia areata were eliminated as the patient's thyroid function tests were normal, the antinuclear and antiSjogren's Abs were negative and the liver biopsy for elevated transaminases was negative for GVHD.
Of note is the fact that the patient was positive for the DQB*301 allele (also present in the donor) only after allo-SCT, which has been previously reported to be significantly associated with alopecia areata and AU. [7] [8] [9] A comparative study of several class II MHC alleles thought to confer resistance or increase susceptibility to alopecia totalis (AT) or AU found that the frequency of the DQB*301allele is significantly increased in patients with AT/AU. The DQB*301 allele presents Ags to T cells and may underlie disease susceptibility for AT/AU. 9 Taken together with the evidence presented by these two cases of AA post allo-SCT, we suggest that alopecia areata can be transferred by T cells in allo-SCT. 
